Phase 1/2a Study Of Bal101553, A Novel Tumor Checkpoint Controller (Tcc), Administered As 48-Hour Infusion In Adult Patients With Advanced Solid Tumors.Markus Joerger,Ioannis Metaxas,Anastasios Stathis,Dagmar Hess,Michael Mark,Franziska Hutter,Nicole Levy,Silvia Stuedeli,Simona Berardi, Michèle Landau-Salzberg,Marc Frederick Engelhardt, Patrice Larger,Thomas Kaindl, Peter Hafner,Phil McKernan,Heidi Lane,Roger von Moos,Cristiana SessaJOURNAL OF CLINICAL ONCOLOGY（2018）引用 1|浏览23暂无评分AI 理解论文溯源树样例生成溯源树，研究论文发展脉络Chat Paper正在生成论文摘要
